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INTRODUCTION
Semisynthetic artemisinin-based thera-
pies are the recommended first-line treat-
ment for P. falciparum malaria, due to
their high efficacy against blood-borne
stages of multidrug-resistant forms of the
parasite (1). Although relatively well tol-
erated in patients, artemisinins are re-
ported to induce neurotoxicity (2) and
embryotoxicity (3) in a number of animal
species, with the latter risk prompting
the contraindication of artemisinin-based
therapies in the first trimester of preg-
nancy unless suitable alternatives are
 unavailable (4). At the cellular level,
artemisinin embryotoxicity appears to in-
volve the selective depletion of primitive
erythroblasts during defined early peri-
ods of gestation (3).
At present there is a lack of consensus
on the pharmacological mechanism of
action of the artemisinins. It is clear,
however, that the endoperoxide bridge
within the 1,2,4-trioxane unit is essential
for antimalarial activity of these com-
pounds, as exemplified by the lack of
 antiparasitic activity associated with
artemisinin counterparts in which the en-
doperoxide moiety is replaced with an
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ether linkage (5). It has been hypothe-
sized that iron-catalyzed reductive cleav-
age of the endoperoxide bridge results in
the generation of toxic carbon-centered
radicals, which alkylate and disrupt
macromolecules that are vital for parasite
homeostasis (6). It also has been pro-
posed that artemisinins are redox-active
molecules and that the intrinsic activity
of the endoperoxide moiety serves to ex-
acerbate levels of oxidative stress within
the parasite by interfering with the func-
tion of important redox-sensitive en-
zymes (7). Inhibition of the parasite
sarco/endoplasmic reticulum calcium
ATPase (SERCA/PfATP6) has been pro-
posed as an alternative mechanism of an-
timalarial activity (8), although this has
been contested (9).
In addition to its critical role in driv-
ing the antiparasitic activity of the
artemis inins, the endoperoxide bridge
appears to represent a toxicophore in
sensitive mammalian cells (10). We have
demonstrated that the selective activa-
tion of the endoperoxide bridge is the
chemical basis for the differential cyto-
toxicity of the synthetic analogue 10β-
(p-bromo phenoxy)dihydroartemisinin
toward sensitive HL-60 promyelocytic
leukemia cells and insensitive periph-
eral blood mononuclear cells (PBMCs)
(11). Bioactivation of the endoperoxide
bridge is sensitive to pharmacological
manipulation of cellular heme levels,
and triggers the generation of reactive
oxygen species (ROS), a process that is
dependent upon the integrity of the mi-
tochondrial electron transport chain
(12). These biochemical events induce
the onset of apoptotic cell death, charac-
terized by mitochondrial membrane de-
polarization, activation of caspases 3
and 7, and DNA fragmentation (11,13).
The limited availability of the Chinese
wormwood Artemisia annua, from which
artemisinin is extracted, and the poor
oral bioavailability of the semisynthetic
artemisinins, have prompted concerted
efforts to develop alternative next-
 generation synthetic endoperoxide-
based drugs (14). Some of the most
promising compounds to emerge from
these efforts are the 1,2,4-trioxolane
OZ439 (15) and our 1,2,4,5-tetraoxane
drug candidate RKA182 (Figure 1),
which has improved pharmacokinetic
properties compared with established
artemisinins (16). It is clear that, as for
the artemisinins, the peroxidic moiety is
essential for the pharmacological action
of tetraoxanes and trioxolanes (17–19),
yet little is known regarding the cyto-
toxic and embryotoxic propensity of
these compounds. Indeed, this was high-
lighted as a key knowledge gap in a
World Health Organization (WHO) re-
port on the safety of  endoperoxide-
based antimalarials (4). To inform the
design of safe and efficacious next-
 generation antimalarials, and with the
ultimate aim of facilitating their optimal
therapeutic utilization, we have evalu-
ated the embryotoxic potential, as well
as the chemical and molecular mecha-
nisms of cytotoxicity, of RKA182 and a
1,2,4-trioxolane equivalent, FBEG100
(Figure 1).
MATERIALS AND METHODS
Materials
Freshly drawn venous blood was col-
lected from healthy volunteers in he-
parinized tubes. Peripheral blood
mononuclear cells (PBMCs) and red
blood cells (RBCs) were isolated using
Lymphoprep (Axis-Shield, Kimbolton,
UK), as described previously (20). ARS
was kindly donated by Dafra Pharma In-
ternational (Turnhout, Belgium). The
anti-caspase 3 antibody (#9662) was ob-
tained from Cell Signaling Technology
(Danvers, MA, USA). Unless noted, all
other reagents were from Sigma-Aldrich
(Poole, UK).
Chemical Synthesis of RKA182 and
FBEG100
The synthesis of RKA182 (16) and
FBEG100 (21) have been described
 previously.
Embryotoxicity Assessment
The protocols described here were un-
dertaken in accordance with criteria out-
lined in a license granted under the Ani-
mals (Scientific Procedures) Act 1986
and approved by the Institution local an-
imal ethics committee. Eleven-wk-old
Crl:CD (Sprague Dawley) male and pri-
miparous female rats were supplied by
Charles River (Kent, UK). Rats were
maintained under standard conditions
(room temperature 21.5 ± 1.5°C, humid-
ity 55 ± 5 %, artificial lighting from 
6 AM to 6 PM, feed and tap water pro-
vided ad libitum). Paired female and
male rats were left in cohabitation from
4 PM to 9 AM the next morning. Mating
is assumed to have occurred at the mid-
point of the dark cycle, hence noon of
the next day is defined as gestation
d 0.5. On gestation d 9.5, pregnant fe-
male rats were euthanized via  increasing
concentrations of CO2 and embryos were
explanted. These were distributed ran-
domly to experimental groups and ex-
posed to the indicated concentrations of
ARS, RKA182 or FBEG100 for 48 h. The
vehicle was methanol, and the concen-
tration of the solvent in the media was
controlled to 0.05%, which is known to
be nonembryotoxic in this model (22).
Embryos were cultured essentially as de-
scribed by New (23), in sterile 50 mL
glass bottles containing four embryos
per bottle in 100% serum (5 mL) col-
lected from male Sprague Dawley rats.
At the start of culture, the bottles were
flushed for 1 min with a gas mixture of
5/5/90% O2/CO2/N2 and placed on a
nonrocking roller mixer (60 rpm) at
37°C. The next morning the bottles were
flushed again with a gas mixture of
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Figure 1. Chemical structures of the
1,2,4,5-tetraoxane RKA182, the 1,2,4-
 trioxolane FBEG100 and the established
artemisinin ARS.
20/5/75% O2/CO2/N2, and in the after-
noon with 40/5/55% O2/ CO2/ N2. The
total culture time was 48 h. At the end of
the culture period the embryos were
transferred into Tyrode salt solution and
examined under a stereomicroscope.
Yolk sac diameter, crown–rump length
and head length were measured and
total morphological scores were as-
signed using the method of Brown and
Fabro (24).
Cull Culture and Treatments
HL-60 cells, RBCs and PBMCs were cul-
tured in RPMI-1640 media supplemented
with 25 mmol/L 4-(2-hydroxyethyl)-1-
piperazine ethanesulfonic acid (HEPES),
300 mg/L L-glutamine, 10% fetal bovine
serum (Biowest, Nuaillé, France),
100 U/mL penicillin and 100 μg/mL
streptomycin. HEK293T, HeLa and
HepG2 cells were cultured in Dulbecco’s
modified Eagle medium (DMEM) supple-
mented with 584 mg/L L-glutamine, 10 %
fetal bovine serum (FBS), 100 U/mL peni-
cillin and 100 μg/mL streptomycin. All
cells were cultured at 37°C in a 5% CO2
atmosphere. For drug treatments, ARS,
RKA182 and FBEG100 were dissolved in
methanol, with the concentration of the
solvent in the media controlled to 0.5%.
For biochemical manipulation experi-
ments, cells were pretreated for 1 h with
succinyl acetone (SA; 1 mmol/L),
δ-aminolevulinic acid (ALA; 1 mmol/L),
protoporphyrin IX (PPIX; 1 μmol/L), 
desferroxamine (DFO; 10 μmol/L), 
holotransferrin (HTF; 10 μmol/L), tiron
(1 mmol/L), N-acetylcysteine (NAC;
10 mmol/L) or Z.VAD.FMK (100 μmol/L),
or for 16 h with buthionine sulphoximine
(BSO; 30 μmol/L), before exposure to the
indicated concentrations of RKA182,
FBEG100 or ARS for a further 24 h.
Quantification of Cell Viability
Cell viability was measured using a
CellTiter-Glo Luminescent Assay
(Promega, Southampton, UK) for adeno-
sine triphosphate (ATP) or a Cytotoxicity
Detection Kit (Roche Applied Science,
Burgess Hill, UK) for lactate dehydroge-
nase (LDH), both in accordance with the
manufacturer’s instructions. The concen-
trations of each compound that induced
a 50% loss of cellular viability (IC50) were
calculated using GraFit (Erithacus Soft-
ware, Horley, UK).
Live-Cell Imaging of
Apoptosis/Necrosis
The ability of RKA182, FBEG100 and
ARS to induce apoptosis/necrosis in ad-
herent HepG2 cells was assessed using a
live-cell fluorescent imaging assay, as
previously described (25). In brief, the
binding of annexin V Alexa Fluor 488
(Life Technologies Corporation, Grand
Island, NY, USA) conjugate to phos-
phatidyl serine on the membranes of
apoptotic cells was followed in real-time
by imaging every 30 min after drug ex-
posure with a BD Pathway 855 imager
(Becton Dickinson, Erembo degem-Aalst,
Belgium). At the same time points, the
intercalation of propidium iodide (PI)
with cellular DNA was quantified. The
total fluorescent intensity per cell area
was quantified using Image Pro (Media
Cybernetics, Bethesda, MD, USA).
Liquid Chromatography Mass
Spectrometry
HL-60 cells were exposed to RKA182
or FBEG100 (both 100 μmol/L) for
0–24 h. Cells and media (100 μL) were
combined with ARS (10 nmol) and ice-
cold acetonitrile (300 μL), vortexed and
centrifuged at 18,000g for 10 min. Ex-
tracted material was filtered using Mul-
tiScreen Solvinert plates (Millipore, Wat-
ford, UK), in accordance with the
manufacturer’s instructions, and ana-
lyzed by multiple reaction monitoring
using an API 4000 QTRAP LC-MS/MS
System (AB Sciex, Warrington, UK) in-
terfaced to a Ultimate 3000 autosampler
and pump (Dionex, Camberly, UK).
The data were collected and analyzed
using Analyst software version 1.5 
(AB Sciex). Sample separation was
achieved on an ACE C8 column (100 ×
2.1 mm, 3 μm; Advanced Chromatogra-
phy Technologies, Aberdeen, UK). The
mobile phase consisted of acetonitrile
with 10 mmol/L ammonium acetate
(90:10, v/v), both supplemented with
0.1% formic acid, delivered at a flow
rate of 0.2 mL/min. The mass spectrom-
eter was operated in positive ion mode.
General operating parameters and ana-
lyte-specific fragmentation transitions
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Figure 2. Embryotoxicity of RKA182, FBEG100 and ARS. (A) Sprague Dawley rat embryos
(gestation d 9.5) were cultured ex vivo for 48 h in the absence or presence of RKA182,
FBEG100 or ARS at the indicated concentrations. Total morphological scores (TMS) were
assigned according to the method of Brown and Fabro (24). Data are expressed relative
to the TMS of embryos exposed only to vehicle (methanol, 0.05%). Data represent mean +
SD, n = 3. (B) Representative stereomicroscope images of embryos with intact visceral yolk
sacs, following exposure to vehicle, RKA182 (3 μmol/L), FBEG100 (3 μmol/L) or ARS
(1 μmol/L) for 48 h. Bar = 1 mm.
are detailed in Tables S1 and S2. Cali-
bration curves for RKA182 and
FBEG100 were generated by plotting the
ratio of peak area for analyte versus in-
ternal standard (ARS), following extrac-
tion from media containing RKA182 or
FBEG100 (1-300 μmol/L) as described
above.
Data Analysis
Data are expressed as mean ± stan-
dard deviation of the mean from at least
three independent experiments. The sig-
nificance of differences within the data
was assessed by one-way analysis of
variance (ANOVA; with the Tukey post
hoc test) or unpaired t test. A P value of
≤0.05 was considered to be statistically
significant.
Supplementary Methods
The synthesis of deoxy-artesunate
(deoxy-ARS), and procedures for deter-
mination of in vitro antiparasitic activity,
flow cytometry, Western blot, DNA frag-
mentation and glutathione content are
described in Supplementary Material.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Embryotoxicity of RKA182, FBEG100
and ARS
To assess the embryotoxic propensity
of the model tetraoxane and trioxolane
compounds, RKA182 and FBEG100, we
utilized the whole embryo culture (WEC)
model, which provides controlled condi-
tions for exposure of live rat embryos to
drugs in the absence of maternal factors.
RKA182, FBEG100 and the artemisinin
ARS were all toxic toward cultured em-
bryos, as indicated by concentration-
 dependent decreases in total morpho-
logical score (incorporating several
indices of embryonic morphological de-
velopment; Figure 2A), visceral yolk sac
diameter, and crown-rump and head
lengths (Supplementary Figure S1). The
IC50 values for RKA182, FBEG100 and
ARS were 4.4, 3.7 and 2.9 μmol/L, re-
spectively. Notably, and in keeping with
previous reports of artem is inin embry-
otoxicity (3), there was a marked pale-
ness to the circulatory system within the
visceral yolk sacs of embryos exposed
to each of the three compounds (Fig -
ure 2B), at both nontoxic and toxic (as
judged by decreases in total morphologi-
cal score) drug concentrations. There-
fore, these data indicate that the deple-
tion of primitive erythroblasts is a
common cellular mechanism that pre-
cedes overt embryotoxicity induced
by artemisinins, tetraoxanes and
 trioxolanes.
Cytotoxicity of RKA182, FBEG100 and
ARS in a Panel of Human Cells
To examine the cytotoxic propensity of
RKA182 and FBEG100, we examined
their effects on the viability of a panel of
human cell lines originating from dis-
tinct organs. In HL-60 promyelocytic
leu kemia cells, which we have used pre-
viously to examine the chemical and
molecular mechanisms of artemisinin
toxicity (11,12), the IC50 values for
RKA182 and FBEG100 were 5- and
18-fold greater, respectively, than ARS
(Table 1, Figure 3A). We also examined
the time-dependency of RKA182,
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Table 1. Cytotoxicity of RKA182, FBEG100, ARS and deoxy-ARS toward a panel of human
cells and antimalarial activities versus P. falciparum.
Cell type RKA182 FBEG100 ARS Deoxy-ARS
HL-60 11.6 ± 4.0a 40.6 ± 3.0 2.2 ± 0.2 >100
HEK293T 14.7 ± 0.2 37.1 ± 2.5 20.1 ± 3.4 >100
HepG2 25.5 ± 5.3 58.8 ± 10.8 77.2 ± 17.2 >100
HeLa 37.7 ± 5.5 55.2 ± 5.6 87.8 ± 11.4 >100
RBC 28.0 ± 7.3 >100 18.9 ± 3.7 >100
PBMC 46.6 ± 0.7 56.8 ± 2.1 >100 >100
P. falciparum (3D7) 4.9 ± 1.2 nmol/Lb,c 1.4 ± 0.3 nmol/L 1.8 ± 0.6 nmol/Lc ND
ND, not determined.
aIC50 values (μmol/L) were calculated from ATP assay concentration-response curves
(Supplementary Figure S3) following incubation with the indicated compound for 24 h.
Data represent mean ± SD, n = 3.
bIn vitro antimalarial activities were calculated against the chloroquine-sensitive 3D7 strain
of P. falciparum.
cSee reference (16).
Figure 3. Concentration and time-dependence of cytotoxicity induced by RKA182,
FBEG100 and ARS in HL-60 cells. (A) Cells were exposed to the indicated concentrations
of RKA182 (black circles), FBEG100 (white circles) or ARS (gray circles) for 24 h, and cyto-
toxicity was determined by quantification of cellular ATP content. Data are expressed rel-
ative to the ATP content of cells exposed only to vehicle (methanol, 0.5%). (B–C) Cells
were exposed to 100 μmol/L of RKA182, FBEG100 or ARS for the indicated times, and cyto-
toxicity was determined by quantification of cellular ATP (B) or LDH (C) contents. Data are
expressed relative to the ATP or LDH content of cells exposed only to vehicle at the corre-
sponding timepoints. All data represent mean + SD, n = 3.
FBEG100 and ARS toxicity. Equimolar
concentrations of RKA182 and FBEG100
both induced rapid (≥ 1 h) concentra-
tion-dependent decreases in cellular ATP
and LDH contents in HL-60 cells,
whereas ARS elicited loss of cellular via-
bility only at ≥16 h (Figures 3B–C, Sup-
plementary Figure S2). RKA182 and
FBEG100 also induced concentration-de-
pendent loss of cell viability in HepG2
hepatocellular carcinoma cells, HeLa cer-
vical adenocarcinoma cells and primary
PBMCs, in all of which ARS demon-
strated lesser toxicity (Table 1, Supple-
mentary Figure S3). In each of the cell
types within the panel, deoxy-ARS had
an IC50 value >100 μmol/L (Table 1, Sup-
plementary Figure S3), demonstrating
the role of the endoperoxide moiety in
the toxicity induced by ARS. Taken to-
gether, all three compounds have cyto-
toxic potential in mammalian cells, yet
exhibit differential timecourses of cell
death and degrees of cell-specificity.
Pathways of Cell Death Induced by
RKA182, FBEG100 and ARS
To explore the pathways of cell death
induced by RKA182 and FBEG100,
HL-60 cells were stained with tetram-
ethylrhodamine ethyl ester (TMRE) fol-
lowing exposure to the compounds for
24 h, and mitochondrial membrane de-
polarization was measured by flow cy-
tometry. Both RKA182 and FBEG100
 induced  concentration-dependent mito-
chondrial membrane depolarization
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Figure 4. Induction of apoptosis by RKA182, FBEG100 and ARS in HL-60 cells. (A) Cells were exposed to the indicated concentrations of
RKA182 (black circles) or FBEG100 (white circles) for 24 h. The number of cells with reduced mitochondrial membrane potential, indicative
of depolarization, was quantified by TMRE staining and flow cytometry, and expressed as percentage of total cells. Data represent mean +
SD, n = 3. (B) Cells were pretreated (triangles) or not (circles) with the caspase inhibitor Z.VAD.FMK (100 μmol/L, 1 h) and then exposed to
the indicated concentrations of ARS (gray symbols), RKA182 (black symbols) or FBEG100 (white symbols) for a further 24 h. As an index of
caspase activity, cleavage of a luminogenic caspase 3/7 substrate was quantified, and expressed as a percentage of the activity in cells
exposed only to vehicle (methanol, 0.5 %). Data represent mean + SD, n = 3. (C) Cells were exposed to methanol (MeOH, 0.5 %), RKA182
(3, 5, 7.5 or 10 μmol/L), FBEG100 (20, 30, 40, 50 μmol/L) or ARS (0.1, 0.3, 1, 3 μmol/L) for 24 h. The processing of caspase 3 from its inactive
32 kDa form to its proteolytically active 17 kDa form was determined in whole cell lysates by Western blotting. Staurosporine (STS; 1 μmol/L)
was used as a positive control for caspase 3 activation. β-Actin was probed as a loading control. (D) Cells were exposed to RKA182 
(55 μmol/L), FBEG100 (75 μmol/L) or ARS (10 μmol/L) for the indicated times. Caspase 3 processing was detected by Western blotting. (E)
Cells were exposed to the indicated concentrations of RKA182 (black circles) or FBEG100 (white circles) for 24 h. The number of cells in
sub-G0/G1 phase of the cell cycle was quantified by PI staining and flow cytometry, and expressed as percentage of total cells. Data rep-
resent mean + SD, n = 3. (F) Cells were pretreated or not with the caspase inhibitor Z.VAD.FMK (100 μmol/L, 1 h) and then exposed to STS
(1 μmol/L), methanol (0.5 %), ARS (1 μmol/L), RKA182 (10 μmol/L) or FBEG100 (40 μmol/L) for a further 24 h. Extracted genomic DNA was
separated by electrophoresis on an agarose gel stained with ethidium bromide. (G) Cells were pretreated (gray bars) or not (black bars)
with the caspase inhibitor Z.VAD.FMK (100 μmol/L, 1 h) and exposed to RKA182, FBEG100 or ARS for a further 24 h. Cytotoxicity was deter-
mined by quantification of cellular ATP content. IC50 values were calculated from concentration-response curves. Unpaired t test, N.S. no
statistically significant increase in IC50 value with Z.VAD.FMK pretreatment. Data represent mean + SD, n = 3.
(Figure 4A). In addition, exposure of
cells to RKA182 and FBEG100, as well
as ARS, resulted in a concentration-de-
pendent increase in the activity of cas-
pases 3 and 7 (Figure 4B), as well as
concentration-dependent (Figure 4C)
and time-dependent (Figure 4D) in-
creases in the processing of caspase 3,
symptomatic of activation of the
 mitochondrial/intrinsic apoptotic path-
way. In all cases, the induction of cas-
pase activity was consistent with the re-
spective profiles of ATP and LDH
depletion (Figures 3B–C), and was abro-
gated by the caspase inhibitor
Z.VAD.FMK (Figure 4B, Supplementary
Figure S4). Cell cycle analysis, per-
formed on PI-stained cells using flow
cytometry, revealed that RKA182 and
FBEG100 induced the concentration-
 dependent formation of a sub-G0/G1
population of cells (Figure 4E), represen-
tative of DNA fragmentation, which was
confirmed by electrophoresis of genomic
DNA isolated from drug-exposed cells
(Figure 4F). The latter effect was inhib-
ited by Z.VAD.FMK (Figure 4F), demon-
strating the functional significance of
caspase processing in the evolution of
drug-induced apoptosis. Taken together,
these data indicate that RKA182,
FBEG100 and ARS induce classical hall-
marks of apoptosis in HL-60 cells.
Notably, Z.VAD.FMK was unable to
protect against the loss of cellular ATP
content induced by RKA182, FBEG100
and ARS in HL-60 cells (Figure 4G), in-
dicating that these compounds also in-
duce a form of caspase-independent cell
death. Indeed, that all three compounds
induced caspase-independent cell death,
reminiscent of necrosis, was confirmed
in adherent HepG2 cells, in spite of pre-
vious reports demonstrating that
artemis inins induce hallmarks of apo-
ptosis in these cells (26,27). In our
hands, HepG2 cells exhibited a similar
phenotype to HL-60 cells, in that
RKA182, FBEG100 and ARS induced a
concentration- dependent decrease in cel-
lular ATP  content (Figure 5A) that was
not abrogated by pretreatment of cells
with Z.VAD.FMK (Figure 5B). By use of 
live-cell fluorescent imaging, a time-
 dependent accumulation of annexin V–
and PI- positive HepG2 cells was ob-
served following exposure to IC50 con-
centrations of RKA182, FBEG100 or ARS
over a 24 h timecourse (Figures 6A–D).
In each case, PI staining increased prior
to, or simultaneously with, the accumu-
lation of  annexin V–positive cells, while
neither  signal (Figures 6A–D), nor overall
cyto toxicity (Figure 5B), was affected by
Z.VAD.FMK. In contrast, the apoptosis-
inducing compound cisplatin induced
the accumulation of annexin V–positive
cells prior to an increase in PI staining,
and both signals were diminished by
Z.VAD.FMK (Figure 6E). In all, these
data indicate that RKA182, FBEG100
and ARS induce mammalian cell death
that bears the hallmarks of caspase-
 dependent apoptosis, but that caspase-
independent necrosis also contributes to
the overall toxicity of these compounds
in sensitive cells.
Role of Heme and Iron in the
Mechanism of RKA182 and ARS
Cytotoxicity
In light of the similar pathways of cell
death induced by RKA182 and FBEG100
in sensitive mammalian cells, and previ-
ous reports demonstrating a role for
heme and iron in the mechanism of
artemisinin toxicity (6,12,28,29), we ex-
amined the importance of these biochem-
ical factors in the cell death induced by
RKA182 in comparison to ARS. In keep-
ing with our previous report that inhibi-
tion of heme synthesis protects against
artemisinin toxicity in mammalian cells
(12), here the δ-aminolevulinate dehy-
dratase inhibitor SA perturbed the ability
of ARS and RKA182 to induce cytotoxic-
ity (Figure 7A) and caspase 3/7 activa-
tion (Supplementary Figure S5) in HL-60
cells. Furthermore, the heme precursors
ALA and PPIX augmented the toxic ef-
fects of ARS and, to a greater extent,
RKA182 (Figure 7A). The ability of ALA
to enhance the toxicity of ARS and
RKA182 was dependent on its incorpora-
tion into heme, as SA reversed the ALA-
induced exacerbation of toxicity, but had
no effect on the ability of PPIX to en-
hance toxicity, for either compound (Fig-
ure 7A). We next probed the role of iron
in the toxicity induced by ARS and
RKA182. Pretreatment of HL-60 cells
with the iron chelator DFO provided
substantial protection against the toxic
effects of ARS and RKA182 (Figure 7B),
as well as inhibiting the ability of these
compounds to induce caspase 3/7 activa-
tion (Supplementary Figure S5). Pretreat-
ment of cells with HTF, an exogenous
source of Fe(II), had no discernable effect
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Figure 5. Cytotoxicity of RKA182, FBEG100 and ARS in HepG2 cells. (A) Cells were exposed
to the indicated concentrations of RKA182 (black circles), FBEG100 (white circles) or ARS
(gray circles) for 24 h, and cytotoxicity was determined by quantification of cellular ATP
content. Data are expressed relative to the ATP content of cells exposed only to vehicle
(methanol, 0.5%). (B) Cells were pretreated (gray bars) or not (black bars) with the cas-
pase inhibitor Z.VAD.FMK (100 μmol/L, 1 h) and exposed to RKA182, FBEG100 or ARS for a
further 24 h. Cytotoxicity was determined by quantification of cellular ATP content. IC50
values were calculated from concentration-response curves. Unpaired t test, N.S. no statis-
tically significant increase in IC50 value with Z.VAD.FMK pretreatment. Data represent
mean + SD, n = 3.
on ARS toxicity (Figure 7B), in keeping
with our previous report (12), but HTF
did enhance RKA182 toxicity (Figure 7B).
These results indicate that heme and iron
play important roles in the mechanism of
toxicity of ARS and RKA182 (Figure 7F),
although the latter is more sensitive to
exacerbation of normal cellular heme
and iron levels.
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Figure 6. Induction of caspase-independent necrosis by RKA182, FBEG100 and ARS in HepG2 cells. Cells were pretreated (white symbols)
or not (black symbols) with the caspase inhibitor Z.VAD.FMK (100 μmol/L, 1 h) and exposed to vehicle (methanol, 0.5%; A), RKA182
(20 μmol/L; B), FBEG100 (60 μmol/L; C), ARS (70 μmol/L; D) or cisplatin (10 μmol/L; E) for a further 24 h. To follow cell death in real-time,
 annexin V Alexa Fluor 488 (circles) and PI (triangles) staining was measured by live-cell fluorescent imaging at the indicated time points.
The total fluorescent intensity of each signal is expressed per cell area. Representative images of annexin and PI signals at the indicated
time points, in the absence and presence of Z.VAD.FMK, are presented below the relevant charts.
Role of Oxidative Stress in the
Mechanism of RKA182 and ARS
Cytotoxicity
Previously, we have shown that
artemisinins induces concentration and
time-dependent elevations of ROS in
mammalian cells, and that the superoxide
scavenger tiron protects against the toxic-
ity of these compounds (12). In keeping
with these observations, here both ARS
and RKA182 toxicity was diminished by
tiron and the thiol antioxidant NAC in
HL-60 cells (Figure 7C, Supplementary
Figure S5). To further probe the involve-
ment of oxidative stress in the toxicity
 induced by ARS and RKA182, we pre-
treated HL-60 cells with BSO, an inhibitor
of glutathione biosynthesis (30). BSO pro-
voked glutathione depletion (Figure 7D)
and augmented the cytotoxic action of
ARS and RKA182, an effect that was re-
versed by coincubation with NAC (Fig-
ure 7E). Taken together, these data indi-
cate that oxidative stress is an important
mechanistic component of ARS and
RKA182 -induced cell death (Figure 7F).
Role of Chemical Decomposition in
RKA182 and FBEG100 Cytotoxicity
Previously, we have shown that the
selective activation of the endoperoxide
bridge is the chemical basis for the dif-
ferential cytotoxicity of a model
artemisinin toward sensitive HL-60 cells
and insensitive PBMCs (11). Further-
more, we have reported ≥30% decompo-
sition of the model artemisinin 10β-(p-
fluorophenoxy) dihydroartemisinin in
sensitive mammalian cells under condi-
tions of marked cytotoxicity (12). In con-
trast, here there was no discernable
change in the amount of RKA182 recov-
ered following exposure of HL-60 cells
for up to 24 h, despite induction of 
significant cytotoxicity within 1 h (Fig-
ure 8A). Furthermore, there was no evi-
dence for general decomposition of
RKA182 following exposure to HL-60
cells pretreated with ALA, PPIX or HTF
(data not shown), despite each pretreat-
ment enhancing the overall cytotoxicity
of RKA182 (Figures 7A–B). The level of
FBEG100 did decline steadily over a 24 h
timecourse (Figure 8B), however this
was attributed to spontaneous decompo-
sition in cell culture media (Figure 8C),
and importantly there was no change in
the amount of FBEG100 recovered from
cells at early timepoints in which signifi-
cant losses of ATP content were recorded
(Figure 8B). In the absence of a suitable
chemical marker of bioactivation, these
data do not exclude the possibility of a
specific bioactivation process underlying
the toxicity of trioxolanes and tetraox-
anes. However, in contrast to model
artemisinins, the ability of these com-
pounds to induce cell death does appear
to be relatively independent of general
chemical decomposition.
DISCUSSION
Synthetic trioxolanes and tetraoxanes
have shown promise as next-generation
antimalarial drug candidates, particu-
larly in terms of therapeutic efficacy and
lack of synthetic constraints. Indeed, we
recently have identified the tetraoxane
drug candidate RKA182 that possesses
improved pharmacokinetic properties
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Figure 7. Role of heme, iron and oxidative stress in RKA182 and ARS toxicity. (A) HL-60 cells
were pretreated or not for 1 h with the δ-aminolevulinate dehydratase inhibitor SA 
(1 mmol/L) and/or the heme precursors ALA (1 mmol/L) or PPIX (1 μmol/L), before a fur-
ther 24-h exposure to ARS (2 μmol/L) or RKA182 (10 μmol/L). (B) HL-60 cells were pre-
treated or not for 1 h with the iron chelator DFO (10 μmol/L) or the exogenous iron source
HTF (10 μmol/L), before a further 24-h exposure to ARS (10 μmol/L) or RKA182 (15 μmol/L).
(C) HL-60 cells were pretreated or not for 1 h with the superoxide scavenger tiron 
(1 mmol/L) or the thiol antioxidant NAC (10 mmol/L), before a further 24-h exposure to
ARS (30 μmol/L) or RKA182 (20 μmol/L). (D–E) Cells were pretreated or not for 16 h with the
glutathione synthesis inhibitor BSO (30 μmol/L), followed by a further 1-h exposure to NAC
(10 mmol/L). (D) Total glutathione content was determined using the DTNB recycling
assay, and is normalized to total protein content. (E) Cells were subsequently exposed to
ARS (1 μmol/L) or RKA182 (2 μmol/L) for a further 24 h. In all cases,  cytotoxicity was deter-
mined by quantification of cellular ATP content. Data are expressed relative to the ATP
content of cells exposed only to vehicle (methanol, 0.5%). All data represent mean + SD, 
n = 3. One-way ANOVA, *P ≥ 0.05, **P ≥ 0.01, ***P ≥ 0.001 versus non-pretreated cells, or for
the indicated comparison, N.S., no statistically significant change in ATP content with indi-
cated pretreatment. (F) Proposed mechanisms underpinning cytotoxicity induced by
artemisinins, trioxolanes and tetraoxanes.
and outstanding antimalarial activity
(16). In addition, a number of trioxolane
and tetraoxane compounds currently are
being supported by the Medicines for
Malaria Venture (MMV) and/or are in
clinical trials (15,31), yet the continuing
development and optimal therapeutic
utilization of these compounds must be
supported by an understanding of their
potential to induce cytotoxicity in mam-
malian cells, and an appreciation of the
underpinning chemical and molecular
mechanisms. Here, we have revealed
that, similarly to the established artem -
isinin ARS, both RKA182 and its triox-
olane counterpart FBEG100 can induce
embryotoxicity in the rodent WEC
model, as well as cytotoxicity across a
panel of primary and established human
cells. These findings may have important
implications for the continuing develop-
ment and ultimate therapeutic utilization
of these promising antimalarial drug
candidates.
P. falciparum infection during preg-
nancy poses a significant health risk to
both the mother and unborn child (32),
yet artemisinin-based therapies are cur-
rently contraindicated in the first trimes-
ter of pregnancy due to an increasing
body of evidence indicating that artem -
isinins are embryotoxic in laboratory ani-
mals (3). Here, we have demonstrated
that RKA182 and FBEG100 are embry-
otoxic in the rodent WEC model. Both
compounds, together with ARS, induced
embryotoxicity at >1 μmol/L, in keeping
with previous reports of embryotoxicity
induced by artemisinin (lower limit for
toxicity 0.9 μmol/L) (33), dihydro -
artemisinin (1.8 μmol/L) (34) and the tri-
oxolane OZ277 (1.3 μmol/L) (33). It is
thought that the selective depletion of
primitive erythroblasts, and the anemia
that ensues, is the underlying cause of
artemisinin embryotoxicity in rodents
(3). Indeed, the sensitive period for
artemisinin embryotoxicity in the rat
(gestation d 10–14) correlates with the
timecourse of dependence upon primi-
tive, rather than definitive, erythroblasts
for embryonic oxygen requirements (3).
In keeping with this notion, we observed
that overt embryotoxicity induced by
ARS, RKA182 and FBEG100 was pre-
ceded by a marked paleness within the
visceral yolk sac circulation, indicating
that the targeting of primitive erythrob-
lasts is a common basis for the embry-
otoxicity of artemisinins, tetraoxanes and
trioxolanes. The ultimate risk of embryo -
toxicity in humans can only be estab-
lished through improved translation of
animal data together with robust moni-
toring of inadvertent exposures in preg-
nant patients.
Although the mechanism by which
artemisinins deplete embryonic erythrob-
lasts has yet to be elucidated, it is well
documented that these compounds in-
duce hallmarks of apoptotic cell death in
sensitive mammalian cells in vitro. Here,
we have demonstrated that RKA182,
FBEG100 and ARS induce concentration,
time and caspase-dependent apoptosis in
sensitive cells, while also invoking a
form of caspase-independent cell death
that bears the hallmarks of necrosis. As
such, the ultimate mechanism of cyto -
toxicity appears to be similar for semi-
synthetic artemisinins and synthetic
tetraoxanes and trioxolanes (Figure 7F).
Recently, we and others have demon-
strated the role of heme, iron and ROS in
the pharmacological and toxicological ac-
tions of the artemisinins (6,12,28,29).
Here, oxidative stress was shown to un-
derpin the cytotoxic action of both
RKA182 and ARS, indicating a conver-
gence of mechanism between novel
tetraoxanes and established artemisinins.
Although not tested here, the generation
of oxidative stress could perturb critical,
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Figure 8. Cytotoxicity of RKA182 and FBEG100 is independent of chemical decomposition.
HL-60 cells were exposed to 100 μmol/L RKA182 (A) or 100 μmol/L FBEG100 (B) for the indi-
cated times. Cytotoxicity was determined by quantification of cellular ATP content (black
circles). Data are expressed relative to the ATP content of cells exposed only to vehicle
(methanol, 0.5%) at the corresponding timepoints. Following extraction with acetonitrile at
the indicated timepoints, the amounts of RKA182 and FBEG100 recovered were quanti-
fied by LCMS (white circles), and are expressed relative to the amounts detected at 0 h.
An expansion of the 0–3 h timeframe for FBEG100 is shown below the main chart. All data
represent mean + SD, n = 3. One-way ANOVA, *P ≥ 0.05, ***P ≥ 0.001 versus vehicle-treated
cells (ATP content) or 0 h (LCMS). (C) Cell-free media was supplemented with 100 μmol/L
of RKA182 or FBEG100 and extracted with acetonitrile after 24 h. The amount of RKA182 or
FBEG100 recovered was quantified by LCMS, and is expressed relative to the amount de-
tected at 0 h. All data represent mean + SD, n = 3. One-way ANOVA, ***P ≥ 0.001 decom-
position versus 0 h (LCMS).
but as yet poorly defined, cellular
processes, or provoke the onset of lipid
peroxidation, contributing to the induc-
tion of cell death (7,36–38). We also have
demonstrated that the heme synthesis in-
hibitor SA and the iron chelator DFO di-
minish the toxic effects of ARS and
RKA182, although the latter was rela-
tively less sensitive to these interven-
tions. In contrast, RKA182 toxicity was
relatively more sensitive to elevation of
cellular heme and iron to nonphysiologi-
cal levels.
The above data indicate that tetra -
oxanes are less reliant, relative to artem -
is inins, on interaction with basal levels of
heme and iron for the induction of cyto-
toxicity. However, under conditions of el-
evated heme and/or iron, which are no-
tably associated with malaria infection
(39), tetraoxane toxicity appears to be
augmented to a greater extent than that
of the artemisinins. That such subtle dif-
ferences should exist in the biochemical
mechanisms that underlie the toxic ef-
fects of artemisinins compared with
tetraoxanes and trioxolanes is consistent
with our inability to detect appreciable
chemical decomposition of RKA182 or
FBEG100 under conditions of substantial
cytotoxicity. However, it has been shown
that the peroxidic moiety is essential for
the pharmacological action of tetraox-
anes and trioxolanes (17–19). Therefore,
it is possible that a relatively minor
and/or specific bioactivation, prompted
by interaction with an as yet undefined
cellular target(s), may contribute to the
chemical mechanism of toxicity of these
novel compounds. Further work is there-
fore required to identify suitable chemi-
cal markers of trioxolane and tetraoxane
bioactivation, to fully elucidate the lat-
ter’s role in cytotoxicity.
It is important to note that, at least
based on the ex vivo and in vitro data
presented here, the benefit:risk balance
of these promising antimalarial drug
candidates appears to be considerable,
in terms of the differences between
pharmacologically active and toxic con-
centrations of the compounds. Specifi-
cally, in terms of the ratio between their
IC50 values for embryotoxicity (in the ro-
dent WEC model) and antimalarial ac-
tivity (in the P. falciparum 3D7 screen),
RKA182 (904.1), FBEG100 (2619.3) and
ARS (1630.0) each appear to have excel-
lent therapeutic indices. However, in the
absence of robust in vivo pharmacoki-
netic data for these and other novel syn-
thetic endoperoxide-based antimalarials,
 adverse effects associated with artemis -
inins cannot yet be ruled out with next-
 generation tetraoxane and trioxolane
drug candidates. Such knowledge is par-
ticularly important in light of the pres-
ent focus on the development of syn-
thetic drug candidates with enhanced
stability and bioavailability, which will
increase systemic exposure and the like-
lihood of a single-dose cure for malaria,
but also the potential for toxicity. On the
other hand, in light of proposals that the
sensitivity of cancerous cells to
artemisinin toxicity in vitro be exploited
therapeutically (35), our finding that
model tetraoxanes and trioxolanes are
cytotoxic toward mammalian cells sug-
gests that these compounds also may
represent promising candidates for anti-
cancer therapy.
CONCLUSION
In summary, we have revealed that
model tetraoxane and trioxolane anti-
malarials are embryotoxic in the rodent
WEC model and induce rapid cytotoxic-
ity in mammalian cells. The subtle dif-
ferences in mechanisms and timecourses
of toxicity for these compounds and es-
tablished artemisinins reported here
serve to further emphasize the need to
better understand pharmacological and
toxicological mechanisms of action of
next- generation antimalarial drug can-
didates to enable a more informed as-
sessment of the ultimate risk of adverse
effects in patients. In the continuing
search for more potent endoperoxide-
based antimalarials, it is vital that we
explore and exploit differences in mech-
anisms of action within the parasite and
mammalian cells to ensure the success-
ful development of safe and efficacious
new drugs.
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